OrthoPediatrics Boosts Revenue Guidance on Strong Q1 Growth
Event summary
- Q1 2026 revenue up 13% YoY to $59.4M, with domestic and international growth of 11% and 22%, respectively.
- Adjusted EBITDA turned positive at $2.2M, compared to a loss of $0.4M in Q1 2025.
- Full-year revenue guidance raised to $263M–$267M from prior $262M–$266M range.
- Free cash flow usage reduced by 40% YoY, reflecting improved operational efficiency.
The big picture
OrthoPediatrics’ strong Q1 performance reflects broad-based growth across its pediatric orthopedic portfolio, particularly in trauma and deformity products. The company’s ability to scale operations while improving profitability positions it favorably in a niche but growing segment of the medical device industry.
What we're watching
- Product Innovation Cycle
- The company’s multi-year product super cycle is expected to drive higher ASPs and margin expansion, enhancing hospital partnerships.
- International Expansion
- Sustained 22% international revenue growth suggests potential for further geographic diversification.
- Operational Efficiency
- Whether the company can maintain its improved adjusted EBITDA and free cash flow metrics amid scaling efforts.
Related topics